You Might Like

Benefits of giving Pfizer jab to 5-11-year-olds 'outweigh the risks' Benefits of giving the Pfizer/BioNTech COVID vaccine to 5 to 11-year-olds clearly outweigh the risks, according to a US drug watchdog. Sky News - Published on October 23, 2021
Pfizer-BioNTech vaccine effectiveness wanes to 47% against COVID-19 infection after six months Two doses of the Pfizer-BioNTech vaccine are 90% effective against COVID-19 hospitalisation for at least six months but only 47% effective against infection after that period, according to a new study. Sky News - Published on October 5, 2021
With domestic manufacturing picking up pace, India unlikely to buy Pfizer, Moderna vaccines for now: Sources IndiaTimes - Published on September 22, 2021
Pfizer COVID vaccine trial for children aged under 12 shows 'robust immune response' A Pfizer-BioNTech COVID-19 vaccine trial for children aged between five and 11 has produced "positive results" and has shown a "robust immune response", the two firms have said. Sky News - Published on September 20, 2021
COVID-19 vaccine invites for 12 to 15-year-olds will start being sent out next week The government has accepted the recommendation from the UK's chief medical officers that children aged 12 to 15 should be offered a first dose of the Pfizer/BioNTech coronavirus vaccine and invitations.. Sky News - Published on September 13, 2021
AstraZeneca and Pfizer safe to use as booster jabs, UK medicines regulator says The UK's medicines regulator has said the Pfizer-BioNTech and Oxford-AstraZeneca coronavirus vaccines are safe to use as booster jabs. Sky News - Published on September 9, 2021
COVID-19 pill administered in new Pfizer trial US pharmaceutical giant Pfizer has started giving people doses of a pill against COVID-19 as part of a new clinical trial. Sky News - Published on September 1, 2021
New Zealand reports its first death linked to Pfizer COVID jab New Zealand has reported its first death linked to the Pfizer vaccine after a woman suffered a rare side effect. Sky News - Published on August 30, 2021
Blood clot risk much higher from COVID than from the vaccine, study finds A coronavirus infection presents a much higher risk of developing a blood clot than a first dose of either the AstraZeneca or the Pfizer jab, a study has found. Sky News - Published on August 26, 2021
Teenagers aged between 12 and 15 experienced mild to moderate side effects after Pfizer jab Teenagers aged between 12 and 15 who had the Pfizer jab experienced mild to moderate side effects which cleared up quickly, a study has found. Sky News - Published on August 26, 2021
Protection from COVID-19 jabs wanes within six months, study suggests COVID-19 protection from two doses of the Pfizer or AstraZeneca vaccines begins to wane within six months, new research suggests.   Sky News - Published on August 25, 2021
UK orders 35 million more doses of Pfizer vaccine as it prepares for COVID booster shots The UK has agreed to buy 35 million more doses of the Pfizer-BioNTech vaccine as it prepares to administer booster shots - while the head of the World Health Organisation (WHO) has said booster shots.. Sky News - Published on August 23, 2021
Lancet: Pfizer, AstraZeneca antibody levels start waning after six weeks IndiaTimes - Published on July 27, 2021	COVID-19: EU approves Moderna's vaccine for kids aged 12-17 years This is the second vaccine approved for use on children in Europe. The first vaccine by Pfizer/BioNTech was approved in May. DNA - Published on July 23, 2021
Indian government's expert group in talks with Pfizer over Covid vaccine: Health minister IndiaTimes - Published on July 23, 2021	Eight-week gap between first and second Pfizer doses 'a sweet spot', study finds An eight-week gap between the two doses of the Pfizer vaccine is a "sweet spot", according to new research. Sky News - Published on July 22, 2021
Moderna and Pfizer jabs linked to mild heart inflammation but 'benefits still outweigh risks' The Pfizer/BioNTech and Moderna jabs have been linked to cases of mild heart inflammation - but the benefits still outweigh the risks, according to European and UK health agencies. Sky News - Published on July 9, 2021	Pfizer's UK boss 'comfortable' with plan to lift COVID rules - but will continue to wear a face mask in crowded settings The UK boss of vaccine maker Pfizer says he is "comfortable" with the planned scrapping of most COVID-19 restrictions later this month - but he will continue to wear a mask in crowded settings. Sky News - Published on July 9, 2021
India expects 3-4 million Pfizer, Moderna vaccine doses through Covax by August- sources India expects to receive 3 million to 4 million doses of the Pfizer and Moderna Covid-19 shots through the Covax facility by August, two sources said, as it tries to expand inoculations to prevent.. IndiaTimes - Published on July 7, 2021	Indemnity issue holds up J&J, Pfizer and Moderna jabs IndiaTimes - Published on July 6, 2021
Drug regulator urges Pfizer to apply for Covid-19 vaccine launch in India IndiaTimes - Published on July 6, 2021	Covishield becomes collateral damage in inter-EU tussle over Chinese vaccines EMA has listed 4 vaccines, which are Comirnaty (Pfizer), Janssen, Spikevax (previously COVID-19 Vaccine Moderna), and AstraZeneca's Vaxzevria. DNA - Published on June 29, 2021
India expands vaccine kitty: Moderna gets regulatory nod; Pfizer approval likely soon India on Tuesday cleared the decks for the import of Moderna's Covid vaccine, adding another option to its list of anti-Covid shots. Moderna's vaccine, developed in the United States, will be the.. IndiaTimes - Published on June 29, 2021	'Mixing and matching' Oxford and Pfizer jabs could provide greater COVID protection, study suggests People who have been double-dosed with the Oxford/AstraZeneca vaccine could have a stronger immune response if they were given a different jab as a booster, a leading scientist has said. Sky News - Published on June 28, 2021
Good news! Pfizer gears up to supply 1 billion vaccine doses to India in 2021, approval in "final stages" The Indian government may be set to grant indemnity from liability to Pfizer and Moderna in a bid to fast-track their vaccine's approval. DNA - Published on June 23, 2021	Italian PM receives Pfizer Covid-19 vaccine as 2nd dose after AstraZeneca IndiaTimes - Published on June 23, 2021
America to give 500 million COVID jabs to poorer countries The US is to distribute half a billion shots of the Pfizer vaccine to 100 other countries. Sky News - Published on June 9, 2021	UK medicines regulator approves Pfizer jab for 12 to 15-year-olds The UK's medicines regulator has approved the Pfizer/BioNTech coronavirus vaccine for 12 to 15-year-olds. Sky News - Published on June 4, 2021
Is it worth giving COVID jabs to 12-year-olds? Vaccine experts now face an ethical dilemma The clinical trial results released on Friday by the Medicines and Healthcare products Regulatory Agency (MHRA) show once again just how good the Pfizer-BioNTech vaccine is. Sky News - Published on June 4, 2021	Pfizer jab recipients have lower antibodies targeting Indian variant, study suggests People who have received the Pfizer/BioNTech vaccine have fewer antibodies targeting the Indian COVID-19 variant compared to other strains, new data suggests. Sky News - Published on June 3, 2021
India in talks with Pfizer, J&J, Moderna for local manufacturing of COVID vaccines: Harsh Vardhan Shringla Last month saw India getting the first batches of Suptink V vaccines, which will be also produced by Indian companies. DNA - Published on June 3, 2021	After Pfizer, Serum Institute seeks indemnity over Covid-19 vaccine: Sources Amid discussions over possible legal protection to foreign vaccine manufacturers Pfizer and Moderna over their Covid-19 jabs in India, the Serum Institute of India (SII) has also sought protection.. IndiaTimes - Published on June 3, 2021
India may get Pfizer's vaccine against Covid-19 in July The government's decisions to ease regulatory norms for clearing foreign-made vaccines for use in India and an in-principle consensus on an indemnity waiver are intended to facilitate supply of.. IndiaTimes - Published on June 2, 2021	Over 50 million Pfizer vaccines ready to be delivered to India; talks ongoing for 'partial indemnity' The vaccine - just like other vaccines - can cause an allergic reaction which includes breathing difficulty, fast heartbeat, dizziness, and weakness. DNA - Published on June 2, 2021
DCGI waiver likely to bring foreign vaccines like Pfizer, Moderna a step closer ​In a letter, DCGI Chief VG Somani letter said that this will be applicable for vaccines that have already been approved for restricted use by the US FDA, EMA, UK MHRA, PMDA Japan or listed for.. IndiaTimes - Published on June 2, 2021	Centre dragging feet on granting necessary approvals to Pfizer, Moderna: Sukhbir Singh Badal IndiaTimes - Published on May 29, 2021
Pfizer indicated to provide Covid-19 vaccine in July, requested indemnity against liability: Dr VK Paul IndiaTimes - Published on May 27, 2021	Govt, Pfizer working together for earliest possible import of vaccine: VK Paul "As soon as Pfizer indicated vaccine availability, the central government and the company are working together for the earliest possible import of the vaccine," NITI Aayog member VK Paul, who is also.. IndiaTimes - Published on May 27, 2021
Pfizer tells Centre its vaccine suitable for 12 years and above American pharmaceutical giant Pfizer on Wednesday informs the Central government that its Covid-19 vaccine is suitable for all aged 12 and above and can be stored at 2-8 degrees for over a month,.. IndiaTimes - Published on May 27, 2021	Our vaccine highly effective on Covid-19 variant prevalent in India, suitable for 12 years and above: Pfizer to Govt Seeking a fast-track approval for its Covid-19 vaccine, US major Pfizer has told Indian authorities that its jab has shown "high effectiveness" against the SARS-CoV-2 variant prevalent in India and on.. IndiaTimes - Published on May 26, 2021
Government in talks to boost vaccine arsenal The government is in talks with global vaccine giants Moderna and Pfizer to source Covid-19 shots on an immediate basis, to increase supply in the next two-three months itself. While the Centre expects.. IndiaTimes - Published on May 25, 2021	Moderna's single-dose Covid-19 vaccine in India likely next year; Pfizer ready with 5 crore doses for 2021 Moderna is expecting to launch a single-dose Covid-19 vaccine in India next year and is in talks with Cipla among other Indian firms, while another US giant Pfizer is ready to offer 5 crore shots in.. IndiaTimes - Published on May 25, 2021
Covid-19: Will supply vaccine only to central governments, says Pfizer US-based Covid-19 vaccine manufacturer Pfizer on Monday said it will supply its vaccine only to central governments and "supra-national organisations". "Pfizer will supply Covid-19 vaccine only to.. IndiaTimes - Published on May 24, 2021Also reported by •DNA	Will deal only with Centre: Pfizer, Moderna Massachusetts-based biotechnology company Moderna, which has developed a messenger RNA (mRNA) vaccine to tackle Covid-19, has declined the Punjab government’s request for direct supply of its vaccine.. IndiaTimes - Published on May 23, 2021
Pfizer vaccine nearly 90% effective against Indian variant, 'groundbreaking' study finds The Pfizer coronavirus vaccine is 88% effective against the Indian variant after two doses, a study has found. Sky News - Published on May 22, 2021	Oxford/AstraZeneca vaccine 80% effective against B1.617.2 variant: UK study Two doses from either the Oxford/AstraZeneca or the Pfizer vaccine are over 80 per cent effective in preventing infection from the B1.617.2 variant of Covid-19, first discovered in India, a new UK.. IndiaTimes - Published on May 22, 2021
Delay in second shot of Pfizer vaccine boosts immunity in elderly by over 3 times, finds study IndiaTimes - Published on May 21, 2021